These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 8701811)
1. New generation of prognostic factors in muscle invasive bladder cancer. Abi-Aad AS Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811 [No Abstract] [Full Text] [Related]
2. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
3. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
4. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266 [TBL] [Abstract][Full Text] [Related]
5. [The molecular biology of bladder carcinoma]. Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283 [TBL] [Abstract][Full Text] [Related]
6. [Is protein p53 an independent prognostic factor in bladder carcinoma?]. Keilholz L Strahlenther Onkol; 1995 Sep; 171(9):543-4. PubMed ID: 7570304 [No Abstract] [Full Text] [Related]
7. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851 [TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. Liu L; Zhu D; Gao R; Guo H Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275 [TBL] [Abstract][Full Text] [Related]
10. Gene expression in superficial bladder cancer in a tumor-model-system (RBT). Knopf HJ; von Moorselaar RJ; Debruyne FM; Schalken JA Investig Urol (Berl); 1994; 5():76-9. PubMed ID: 7719325 [No Abstract] [Full Text] [Related]
11. Clear cell carcinoma of the urinary bladder. Lum D Pathology; 2006 Aug; 38(4):367-70. PubMed ID: 16916733 [No Abstract] [Full Text] [Related]
12. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569 [TBL] [Abstract][Full Text] [Related]
13. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745 [TBL] [Abstract][Full Text] [Related]
14. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105 [TBL] [Abstract][Full Text] [Related]
15. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815 [TBL] [Abstract][Full Text] [Related]
16. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726 [TBL] [Abstract][Full Text] [Related]
17. The role of nm23-H1 in the progression of transitional cell bladder cancer. Chow NH; Liu HS; Chan SH Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750 [TBL] [Abstract][Full Text] [Related]
18. [Expression of the tumor suppressor gene p53 in superficial transitional carcinoma of the bladder]. Menéndez López V; Molina Porto R; Alcaráz Asensio A; Alvarez-Vijande García R; Alcover García JA; Ballesta Gimeno MA; Carretero González P Actas Urol Esp; 1998 Sep; 22(8):642-9. PubMed ID: 9835082 [TBL] [Abstract][Full Text] [Related]
19. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. deVere White RW; Katz MH; Steinberg GD J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209 [No Abstract] [Full Text] [Related]
20. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]